Solithromycin

整理：肿瘤资讯 来源：肿瘤资讯 2026年3月21日，“IGNITE全国中青年领航者学术交流会”在美丽的海滨城市湛江顺利召开。本次会议汇聚全国各地消化道肿瘤领域的中青年学术骨干，共同聚焦肿瘤基础转化研究与胃癌精准靶向治疗的前沿进展与临床热点问题。大会内容丰富多彩，涵盖基础机制探索、阴性临床研究反思、再活检时空异质性探讨以及精准靶向治疗的真实世界病例实战四大板块，旨在通过深度的学术交流与思维碰撞，为广大胃癌患者点燃“长生存”的生命之光 。 开场致辞 会议由中山大学肿瘤防治中心邱妙珍教授、中国科学院上海营养与健康研究所秦骏教授、南京鼓楼医院魏嘉教授以及广东医科大学附属医院谢忠教授共同担任大会主席并致开幕辞。主席团对远道而来齐聚湛江的全国专家学者致以诚挚的欢迎。他们表示，期待依托本次会议搭建的高质量交流平台，不仅能充分分享肿瘤基础与转化研究的最新成果，更能深刻剖析临床实践中的难点与困惑。希望与会同仁在此碰撞出前沿思想的火花，携手推动消化道肿瘤个体化精准诊疗水平的稳步提升。 第一环节 驱动免疫系统清除衰老肿瘤细胞的治疗策略  主持：中国科学院上海营养与健康研究所 秦骏教授 讲者：中山大学肿瘤防治中心 王力勤教授 王力勤教授探讨了驱动免疫系统清除衰老肿瘤细胞的创新治疗策略。他指出，放化疗诱导的肿瘤衰老细胞虽停止增殖，但会分泌炎性因子形成慢性炎症微环境，进而抑制T细胞和NK细胞功能、促进肿瘤进展，并引发化疗毒副作用。基于“死了的癌细胞才是好的癌细胞”这一理念，其团队致力于精准剔除这些衰老细胞。 为此，研究团队通过高通量基因文库筛选，发现了c-FLIP和SLC25A23等特异性靶点。针对SLC25A23，团队发现低剂量抗生素Solithromycin能与其稳定结合，并与DR5激活性抗体组成强效的“鸡尾酒疗法”。该疗法可诱发细胞焦亡，释放白介素-18以激活T细胞和NK细胞的免疫监控，从而显著杀伤衰老肿瘤细胞并抑制肿瘤进展。此外，系统性应用该剔除剂还能显著下调全身慢性炎症，有效逆转化疗引起的心脏毒性与体能衰退，在实现增效减毒的同时，也为肺纤维化及机体抗衰老等领域展现出巨大的转化潜力。 胃癌III期阴性研究的系统性反思与前瞻性启示  主持：南京鼓楼医院 魏嘉教授 讲者：郑州大学第一附属医院 贾永旭教授 贾永旭教授系统剖析了近年来消化道肿瘤领域的III期阴性临床研究，为未来药物研发与临床设计提供了宝贵启示。他指出，阴性结果的出现具有必然性，但同样蕴含巨大的指导价值，能帮助研究者识别缺陷、优化策略。贾教授将大型研究失败的原因归纳为三个核心维度。 首先是统计学设计的局限，例如频繁的期中分析会稀释Alpha值，使得原本具有获益趋势的结果无法跨越阳性门槛，提示设定研究终点时须慎之又慎。其次是受试人群的精准匹配不足，胃癌异质性强，不加甄别的全人群入组易掩盖优势亚组的获益，这凸显了伴随诊断前移的绝对必要性。再者是毒副反应对疗效的“稀释”效应，某些联合方案虽初期缓解率优异，但严重的叠加毒性导致大量患者停药，随之而来的疗效折损使其最终未能战胜标准治疗。贾教授呼吁，未来新药研发不能盲目“做加法”，而应聚焦合理的毒性管理、精准的人群定位及严谨的统计学质控，以推动临床思维的真正跃迁。 讨论环节一 本环节由中山大学肿瘤防治中心邱妙珍教授主持，中山大学肿瘤防治中心关文龙教授、南昌大学第一附属医院郭宇玲教授、广东医科大学附属医院彭丽娇教授、安徽医科大学第一附属医院张飞教授、山西省肿瘤医院赵健教授共同参与讨论。各位专家围绕衰老细胞清除技术的转化及阴性临床试验的启迪展开热烈交流。专家们高度肯定了基础探索在减轻治疗毒副作用与重塑免疫微环境中的潜力。针对阴性临床研究，嘉宾们认为，总生存（OS）终点设定的困难、生物标志物亚组的精细区分以及严重毒副反应的管理，是制约研究成败的核心因素。大家普遍强调，面对复杂的肿瘤异质性，临床医生与基础科学家须建立更紧密的合作机制，并呼吁探索临床试验的动态调整设计，在不断试错与反思中真正落实胃癌的精准医疗目标。 第二环节 胃癌临床热议点大家谈 胃癌靶向治疗中的再活检：时空异质性时代的必要选择，还是过度医疗？  主持：南京医科大学第一附属医院 吴昊教授 讲者：华中科技大学同济医学院附属协和医院 林振宇教授 林振宇教授从时空异质性视角，深度论证了晚期胃癌进展期再活检的绝对必要性与临床挑战。他指出，胃癌精准治疗有赖于对靶点的动态把握，但由于原发灶与转移灶间存在显著的空间异质性，加之药物压力引发的时间异质性演变，患者在接受抗HER2或Claudin 18.2等治疗后，靶点表达常出现下调甚至丢失转阴 。单纯依赖有限的内镜样本往往难以反映肿瘤全貌。 结合真实病例，林教授展示了患者在多线治疗后HER2、PD-L1等靶点由全阴转强阳，或高表达耐药后骤降的剧烈波动 。这证明靶点检测绝非“一劳永逸”，在跨线治疗或疾病进展的关键节点积极再活检，是规避盲目用药、制定后续科学方案的必需前提 。尽管面临取材困难等现实阻碍，他仍呼吁临床医生临床迎难而上，并期望未来借助ctDNA液体活检及AI大数据影像预测模型，为破解时空异质性壁垒开辟无创动态监测的新路径。 基于真实病例探讨晚期胃癌精准靶向治疗的临床策略重塑  主持：广东医科大学附属医院 谢忠教授 讲者：山西省肿瘤医院 卢宏霞教授  卢宏霞教授结合三份极具挑战性且病情危重的真实临床病历，生动展示了基于新锐靶点Claudin 18.2的晚期胃癌一线精准治疗是如何成功重塑临床应对策略并缔造生存奇迹的。 首个病例是一位晚期贲门胃底癌患者，合并巨大淋巴结转移、肝脏多发转移、腹膜转移和严重广泛肠梗阻，体能评分逼近终末期且极度消瘦。在全面完善分子标志物检测并确认其Claudin18.2呈现极高表达后，卢教授团队果断为其启动了佐妥昔单抗联合FOLFOX方案的一线抗肿瘤治疗。仅用药数天后，患者梗阻症状便奇迹般迅速缓解，第一周期治疗结束便成功拔除导管并恢复正常进食。随后体重明显增长。随后的影像学复查证实，胃原发灶及转移灶实现了大幅退缩，患者真正体验了绝境逢生的治疗转折。 在第二个致力于追求转化手术的年轻胃癌患者病例中，面对Claudin 18.2高表达且PD-L1具有一定阳性优势的复杂情况，卢教授创新性地采纳了佐妥昔单抗联合双免药物及化疗的四药强效诱导策略。该方案不仅凭借靶免协同增效机制实现了肿瘤标志物的断崖式下降，更以极快的速度降低了局部肿瘤负荷，为患者顺利赢取了接受根治性R0切除手术的宝贵契机。 第三个极晚期病例同样凶险，伴有严重的弥漫性腹膜转移及大量腹水胸水，幸运的是Claudin18.2高表达。患者在接受佐妥昔单抗联合化疗干预后，腹腔积液迅速消退，体感及生存质量得到了颠覆性的改善。 通过这一系列震撼人心的真实世界实践，卢教授深刻阐述了Claudin 18.2靶向药物的问世正在彻底改写晚期胃癌一线生存格局。她强调，尽早完善关键靶点筛查并打破常规思维布局个体化靶向方案，对于伴有急重症并发症的晚期患者而言，往往能够化腐朽为神奇，为他们点亮更长久的生命尊严之光。 讨论环节二 本环节由谢忠教授主持，复旦大学附属中山医院葛步军教授、辽宁省肿瘤医院孟祥宇教授、复旦大学附属华东医院邱继刚教授共同参与讨论。专家们强调，标本离体后的固定时间会直接影响靶点阳性检出率，因此围手术期多学科的紧密衔接至关重要。针对晚期病例，嘉宾们高度认同耐药演变期再活检的临床价值，并充分肯定了佐妥昔单抗在破局胃癌顽固性肠梗阻及重度腹膜转移中展现的惊艳缩瘤效能。此外，专家们还深入探讨了维持期静脉转口服方案的过渡、老年患者的个体化减量，以及多靶点共表达时的科学排兵布阵等临床迫切议题，重申了以患者获益为核心的动态精准施治原则。 会议总结 在大会的最后阶段，魏嘉教授与秦骏教授对本次学术交流会的丰硕成果进行了高度凝练的总结致辞。两位主席一致表示，本次会议内容充实、切中要害，从基础细胞衰老机制的前沿转化，到宏观阴性临床试验的深刻反思，再到直击时空异质性盲区及真实世界绝境逢生的策略重塑，无不彰显了中青年领航专家们对科学真理的执着探求与深邃的学术洞察。自由而热烈的跨学科对话不仅理清了众多长久困扰临床的决策迷雾，更为后续研究指明了破局的方向。期待借由此类高质量学术平台的不断延伸，未来能凝聚更多中坚力量，持续催生出贴近临床痛点的科研突破，让精准医疗的火炬薪火相传，点燃更多消化道肿瘤患者的治愈希望。 仅供医疗卫生等专业人士参考审批编号： MAT-CN-VYL-2026-00063材料准备时间：2026-3-26材料到期时间：2027-3-26 责任编辑：肿瘤资讯-Linda 排版编辑：肿瘤资讯-XF 版权声明 版权归肿瘤资讯所有。欢迎个人转发分享，其他任何媒体、网站如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明“转自：良医汇-肿瘤医生APP”。

BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development. "We are thrilled to welcome Chris to our Board of Directors," said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadership will be critical as we prepare for our first commercial launch in Becker muscular dystrophy and advance our cardiovascular asset to Phase 3. Prior to joining the Edgewise Board, Mr. Martin served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October of 2025. As CCO, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre® (ensifentrine). Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI® (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan® marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's product candidates and programs, including sevasemten, EDG-7500 and EDG-15400; statements regarding Edgewise's ability to commercialize sevasemten; statements regarding Edgewise's ability to advance its cardiovascular asset to Phase 3; and statements by Edgewise's President and Chief Executive Officer. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise's limited operating history, its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having generated any revenue to date; Edgewise's ability to achieve objectives relating to the discovery, development and commercialization of its product candidates, if approved; Edgewise's need for substantial additional capital to finance its operations; Edgewise's substantial dependence on the success of sevasemten and EDG-7500; Edgewise's ability to develop and commercialize sevasemten, EDG-7500 and EDG-15400; risks related to Edgewise's clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise's product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise's clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks relating to interim, topline and preliminary data from Edgewise's clinical trials changing as more patient data becomes available; risks related to failure to develop a proprietary drug discovery platform; risks related to exposure to additional risk if we develop sevasemten and potential other programs in connection with other therapies; risks related to production of drugs by Edgewise's third-party manufacturers; risks related to changes in methods of product candidate manufacturing or formulation; risks related to not achieving adequate market acceptance; risks related to the patient population for our product candidates having a small patient population; risks related to the regulatory approval processes of domestic and foreign authorities being lengthy, time consuming and inherently unpredictable; risks relating to disruptions at the FDA, the SEC and other government agencies; risks relating to Edgewise's ability to attract and retain highly skilled executive officers and employees; Edgewise's ability to obtain and maintain intellectual property protection for its product candidates; Edgewise's reliance on third parties; risks related to future acquisitions or strategic partnerships; risks related to general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-302620999.html SOURCE Edgewise Therapeutics